1
|
Rittavee Y, Artus J, Desterke C, Simanic I, de Souza LEB, Riccaldi S, Coignard S, Ijjeh Y, Hugues P, Bennaceur-Griscelli A, Turhan AG, Foudi A. miR-495-3p sensitizes BCR-ABL1-expressing leukemic cells to tyrosine kinase inhibitors by targeting multidrug resistance 1 gene in T315I mutated cells. Exp Hematol 2023; 118:40-52. [PMID: 36535407 DOI: 10.1016/j.exphem.2022.12.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2022] [Revised: 12/08/2022] [Accepted: 12/11/2022] [Indexed: 12/23/2022]
Abstract
Chronic myeloid leukemia (CML) is a clonal hematopoietic malignancy driven by the BCR-ABL1 fusion oncoprotein. The development of tyrosine kinase inhibitors (TKIs) has deeply increased long-term survival of CML patients. Nonetheless, one patient out of four will switch TKI off owing either to drug intolerance or resistance partly due to amplification or mutations of BCR-ABL1 oncogene and alteration in ATP-binding cassette (ABC) transporters. Increasing evidence suggests the involvement of the microRNA miR-495-3p in cancer-associated chemoresistance through multidrug resistance 1 (MDR1) gene, which encodes an ATP-dependent efflux pump. Our study aimed at investigating the potential role of miR-495-3p in CML TKI chemo-sensitivity and determining the underlying molecular circuitry involved. We first observed that miR-495-3p expression was lower in BCR-ABL1-expressing cellular models in vitro. Notably, loss-of-function experiments showed increased proliferation associated with a decreased number of nondividing cells (G0/G1) and resistance to Imatinib. Conversely, our data showed that miR-495-3p overexpression hindered leukemic cell growth and TKI resistance in Imatinib-resistant T315I-mutant cells, as well as drug efflux activity through MDR1 regulation. Further investigating the role of miR-495-3p in CML patients, we found that predicted miR-495-3p targets were upregulated in patients in blast crisis that were involved in protein phosphorylation and associated with the worst prognosis. Taken together, our results demonstrate that downregulation of miR-495-3p expression is important in the malignant phenotype of CML and TKI resistance mechanisms and could be a useful biomarker and a potential therapeutic target to eradicate CML.
Collapse
MESH Headings
- Humans
- Imatinib Mesylate/pharmacology
- Fusion Proteins, bcr-abl/genetics
- Fusion Proteins, bcr-abl/metabolism
- Tyrosine Protein Kinase Inhibitors
- Protein Kinase Inhibitors/pharmacology
- Protein Kinase Inhibitors/therapeutic use
- Cell Line, Tumor
- Drug Resistance, Neoplasm/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- MicroRNAs/genetics
- MicroRNAs/metabolism
- Drug Resistance, Multiple
- Adenosine Triphosphate
Collapse
Affiliation(s)
- Yutthana Rittavee
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; ATIP/Avenir INSERM UMRS-1310, Paris Saclay University, Villejuif, France; Paris Saclay University, Faculty of Medicine, Kremlin-Bicêtre, France
| | - Jérôme Artus
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; ATIP/Avenir INSERM UMRS-1310, Paris Saclay University, Villejuif, France; Paris Saclay University, Faculty of Medicine, Kremlin-Bicêtre, France
| | - Christophe Desterke
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; Paris Saclay University, Faculty of Medicine, Kremlin-Bicêtre, France; INGESTEM National iPSC Infrastructure, Villejuif, France; INGESTEM National iPSC Infrastructure, Villejuif, France
| | - Isidora Simanic
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; ATIP/Avenir INSERM UMRS-1310, Paris Saclay University, Villejuif, France
| | - Lucas Eduardo Botelho de Souza
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; ATIP/Avenir INSERM UMRS-1310, Paris Saclay University, Villejuif, France
| | - Sandra Riccaldi
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; ATIP/Avenir INSERM UMRS-1310, Paris Saclay University, Villejuif, France
| | - Sabrina Coignard
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; ATIP/Avenir INSERM UMRS-1310, Paris Saclay University, Villejuif, France
| | - Yousef Ijjeh
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; ATIP/Avenir INSERM UMRS-1310, Paris Saclay University, Villejuif, France
| | - Patricia Hugues
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; ATIP/Avenir INSERM UMRS-1310, Paris Saclay University, Villejuif, France
| | - Annelise Bennaceur-Griscelli
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; Paris Saclay University, Faculty of Medicine, Kremlin-Bicêtre, France; APHP Paris Saclay, Department of Hematology, Hôpital Bicêtre and Paul Brousse, Villejuif, France; INGESTEM National iPSC Infrastructure, Villejuif, France; CITHERA, Centre for IPSC Therapies, INSERM UMS-45, Paris Saclay University, Genopole, Evry, France
| | - Ali G Turhan
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; Paris Saclay University, Faculty of Medicine, Kremlin-Bicêtre, France; APHP Paris Saclay, Department of Hematology, Hôpital Bicêtre and Paul Brousse, Villejuif, France; INGESTEM National iPSC Infrastructure, Villejuif, France; CITHERA, Centre for IPSC Therapies, INSERM UMS-45, Paris Saclay University, Genopole, Evry, France
| | - Adlen Foudi
- INSERM UMRS-1310, Paris Saclay University, Villejuif, France; ATIP/Avenir INSERM UMRS-1310, Paris Saclay University, Villejuif, France; Paris Saclay University, Faculty of Medicine, Kremlin-Bicêtre, France.
| |
Collapse
|
2
|
Bhukhai K, Fouquet G, Rittavee Y, Tanhuad N, Lakmuang C, Borwornpinyo S, Anurathapan U, Suksamrarn A, Piyachaturawat P, Chairoungdua A, Hermine O, Hongeng S. Enhancing Erythropoiesis by a Phytoestrogen Diarylheptanoid from Curcuma comosa. Biomedicines 2022; 10:biomedicines10061427. [PMID: 35740448 PMCID: PMC9219836 DOI: 10.3390/biomedicines10061427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2022] [Revised: 05/31/2022] [Accepted: 06/03/2022] [Indexed: 11/16/2022] Open
Abstract
Erythropoietin (Epo) is widely used for the treatment of anemia; however, non-hematopoietic effects and cancer risk limit its clinical applications. Therefore, alternative molecules to improve erythropoiesis in anemia patients are urgently needed. Here, we investigated the potential effects of a phytoestrogen diarylheptanoid (3R)-1,7-diphenyl-(4E,6E)-4,6-heptadien-3-ol, (ASPP 049) isolated from Curcuma comosa on promoting erythropoiesis. Treatment with C. comosa extract improved anemia symptoms demonstrated by increasing red blood cell numbers, hematocrit, and hemoglobin content in anemic mice. In addition, ASPP 049, the major compound isolated from C. comosa, enhanced the suboptimal Epo dosages to improve erythroid cell differentiation from hematopoietic stem cells, which was inhibited by the estrogen receptor (ER) antagonist, ICI 182,780. Moreover, the ASPP 049-activated Epo-Epo receptor (EpoR) complex subsequently induced phosphorylation of EpoR-mediated erythropoiesis pathways: STAT5, MAPK/ERK, and PI3K/AKT in Epo-sensitive UT-7 cells. Taken together, these results suggest that C. comosa extract and ASPP 049 increased erythropoiesis through ER- and EpoR-mediated signaling cascades. Our findings provide insight into the specific interaction between a phytoestrogen diarylheptanoid and Epo-EpoR in a hematopoietic system for the potential treatment of anemia.
Collapse
Affiliation(s)
- Kanit Bhukhai
- Department of Physiology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand; (N.T.); (P.P.); (A.C.)
- Correspondence: (K.B.); (S.H.); Tel.: +66-22015614 (K.B.); +66-22011495 (S.H.)
| | - Guillemette Fouquet
- Institut Hospitalo-Universitaire Imagine, Université Sorbonne Paris Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Necker, 75015 Paris, France; (G.F.); (O.H.)
- INSERM U1163 and CNRS ERL8254, Université Paris Descartes, Faculté de Médecine, Hôpital Necker, 75015 Paris, France
| | - Yutthana Rittavee
- Department of Biology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand;
| | - Nopmullee Tanhuad
- Department of Physiology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand; (N.T.); (P.P.); (A.C.)
| | - Chaiyaporn Lakmuang
- Department of Chemistry, Faculty of Science, Mahidol University, Bangkok 10400, Thailand;
| | - Suparerk Borwornpinyo
- Department of Biotechnology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand;
- Excellent Center for Drug Discovery, Mahidol University, Bangkok 10400, Thailand
| | - Usanarat Anurathapan
- Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand;
| | - Apichart Suksamrarn
- Department of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of Science, Ramkhamhaeng University, Bangkok 10240, Thailand;
| | - Pawinee Piyachaturawat
- Department of Physiology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand; (N.T.); (P.P.); (A.C.)
| | - Arthit Chairoungdua
- Department of Physiology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand; (N.T.); (P.P.); (A.C.)
- Excellent Center for Drug Discovery, Mahidol University, Bangkok 10400, Thailand
| | - Olivier Hermine
- Institut Hospitalo-Universitaire Imagine, Université Sorbonne Paris Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Necker, 75015 Paris, France; (G.F.); (O.H.)
- INSERM U1163 and CNRS ERL8254, Université Paris Descartes, Faculté de Médecine, Hôpital Necker, 75015 Paris, France
- Laboratory of Excellence GReX, 75015 Paris, France
- Service d’Hématologie Clinique Adultes, Assistance Publique-Hôpitaux de Paris, Hôpital Necker, 75015 Paris, France
| | - Suradej Hongeng
- Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand;
- Correspondence: (K.B.); (S.H.); Tel.: +66-22015614 (K.B.); +66-22011495 (S.H.)
| |
Collapse
|